TY  - JOUR 
AU  - González López, Tomás José
AU  - Sánchez González, Blanca
AU  - Jarque, Isidro
AU  - Bernat, Silvia
AU  - Fernández Fuertes, Fernando
AU  - Caparrós, Isabel
AU  - Soto, Inmaculada
AU  - Fernández Rodríguez, Angeles
AU  - Bolaños, Estefanía
AU  - Pérez Rus, Gloria
AU  - Pascual, Cristina
AU  - Hernández Rivas, José Angel
AU  - López Ansoar, Elsa
AU  - Gómez Nuñez, Marta
AU  - Martínez Robles, Violeta
AU  - Olivera, Pavel
AU  - Yera Cobo, Maria
AU  - Peñarrubia, María Jesús
AU  - Fernández Miñano, Carmen
AU  - Cabo, Erik
AU  - Martínez Badas, María Paz
AU  - Perdomo Hernández, Germán M.
AU  - García Frade, Luis Javier
PY  - 2020
SN  - 0902-4441
UR  - http://hdl.handle.net/10259/5243
AB  - Background
Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old...
LA  - eng
PB  - John Wiley & Sons
KW  - elderly
KW  - eltrombopag
KW  - immune thrombocytopenia
KW  - primary
KW  - secondary
KW  - Sistema cardiovascular-Enfermedades
KW  - Cardiovascular system-Diseases
TI  - Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
DO  - 10.1111/ejh.13370
T2  - European Journal of Haematology
VL  - 104
M2  - 259
ER  -